Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors
来源期刊：Investigational New DrugsDOI：10.1007/s10637-019-00771-x
Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma
来源期刊：Investigational New DrugsDOI：10.1007/s10637-019-00830-3
Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan
来源期刊：Investigational New DrugsDOI：10.1007/s10637-019-00801-8
LEF1-AS1 contributes to proliferation and invasion through regulating miR-544a/ FOXP1 axis in lung cancer
来源期刊：Investigational New DrugsDOI：10.1007/s10637-018-00721-z
Cardamonin, a natural chalcone, reduces 5-fluorouracil resistance of gastric cancer cells through targeting Wnt/β-catenin signal pathway
来源期刊：Investigational New DrugsDOI：10.1007/s10637-019-00781-9
Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial
来源期刊：Investigational New DrugsDOI：10.1007/s10637-019-00755-x
Phase I study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer
来源期刊：Investigational New DrugsDOI：10.1007/s10637-018-0634-5
A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma
来源期刊：Investigational New DrugsDOI：10.1007/s10637-019-00844-x
The exosome secretion inhibitor neticonazole suppresses intestinal dysbacteriosis-induced tumorigenesis of colorectal cancer
来源期刊：Investigational New DrugsDOI：10.1007/s10637-019-00759-7
Knockdown of FBXO22 inhibits melanoma cell migration, invasion and angiogenesis via the HIF-1α/VEGF pathway
来源期刊：Investigational New DrugsDOI：10.1007/s10637-019-00761-z
Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1–ALK fusion: a case report
来源期刊：Investigational New DrugsDOI：10.1007/s10637-019-00742-2
Apoptosis induction and cell cycle arrest of pladienolide B in erythroleukemia cell lines
来源期刊：Investigational New DrugsDOI：10.1007/s10637-019-00796-2
Novel palladium (II) complexes with tetradentate thiosemicarbazones. Synthesis, characterization, in vitro cytotoxicity and xanthine oxidase inhibition
来源期刊：Investigational New DrugsDOI：10.1007/s10637-019-00751-1
A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer
来源期刊：Investigational New DrugsDOI：10.1007/s10637-019-00731-5
Screening, identification of prostate cancer urinary biomarkers and verification of important spots
来源期刊：Investigational New DrugsDOI：10.1007/s10637-018-0709-3
Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML
来源期刊：Investigational New DrugsDOI：10.1007/s10637-019-00786-4
Anticancer activity, apoptosis and a structure–activity analysis of a series of 1,4-naphthoquinone-2,3-bis-sulfides
来源期刊：Investigational New DrugsDOI：10.1007/s10637-019-00775-7
Microarray expression profiles and bioinformatics analysis of mRNAs, lncRNAs, and circRNAs in the secondary temozolomide-resistant glioblastoma
来源期刊：Investigational New DrugsDOI：10.1007/s10637-019-00884-3
The influence of the coadministration of the p-glycoprotein modulator elacridar on the pharmacokinetics of lapatinib and its distribution in the brain and cerebrospinal fluid
来源期刊：Investigational New DrugsDOI：10.1007/s10637-019-00806-3
Synergistic effect and reduced toxicity by intratumoral injection of cytarabine-loaded hyaluronic acid hydrogel conjugates combined with radiotherapy on lung cancer
来源期刊：Investigational New DrugsDOI：10.1007/s10637-019-00740-4
Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours
来源期刊：Investigational New DrugsDOI：10.1007/s10637-019-00787-3
Evaluation of absorption, distribution, metabolism, and excretion of [14C]-rucaparib, a poly(ADP-ribose) polymerase inhibitor, in patients with advanced solid tumors
来源期刊：Investigational New DrugsDOI：10.1007/s10637-019-00815-2
A preclinical evaluation of thiostrepton, a natural antibiotic, in nasopharyngeal carcinoma
来源期刊：Investigational New DrugsDOI：10.1007/s10637-019-00779-3
Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials
来源期刊：Investigational New DrugsDOI：10.1007/s10637-019-00736-0
A high-throughput drug screen identifies auranofin as a potential sensitizer of cisplatin in small cell lung cancer
来源期刊：Investigational New DrugsDOI：10.1007/s10637-019-00750-2
Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2)
来源期刊：Investigational New DrugsDOI：10.1007/s10637-019-00857-6
A phase Ib study of a PI3Kinase inhibitor BKM120 in combination with panitumumab in patients with KRAS wild-type advanced colorectal cancer
来源期刊：Investigational New DrugsDOI：10.1007/s10637-019-00814-3
The cellular effects of novel triazine nitrogen mustards in glioblastoma LBC3, LN-18 and LN-229 cell lines
来源期刊：Investigational New DrugsDOI：10.1007/s10637-018-0712-8
The tumor suppressor NDRG2 cooperates with an mTORC1 inhibitor to suppress the Warburg effect in renal cell carcinoma
来源期刊：Investigational New DrugsDOI：10.1007/s10637-019-00839-8
7-Chloroquinoline-1,2,3-triazoyl carboxamides induce cell cycle arrest and apoptosis in human bladder carcinoma cells
来源期刊：Investigational New DrugsDOI：10.1007/s10637-019-00861-w
A phase I dose-reduction study of apatinib combined with pemetrexed and carboplatin in untreated EGFR and ALK negative stage IV non-squamous NSCLC
来源期刊：Investigational New DrugsDOI：10.1007/s10637-019-00811-6
Correction to: Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial
来源期刊：Investigational New DrugsDOI：10.1007/s10637-019-00773-9
The influence of prior ramucirumab treatment on the clinical activity of FOLFIRI as third-line therapy in patients with metastatic gastric Cancer
来源期刊：Investigational New DrugsDOI：10.1007/s10637-019-00725-3
Switch maintenance therapy with S-1 after induction therapy with carboplatin and nanoparticle albumin-bound paclitaxel in advanced lung squamous cell carcinoma
来源期刊：Investigational New DrugsDOI：10.1007/s10637-019-00747-x
Phase II study of apatinib, a novel tyrosine kinase inhibitor targeting tumor angiogenesis, as second-line treatment for recurrent or advanced cervical cancer patients
来源期刊：Investigational New DrugsDOI：10.1007/s10637-019-00858-5
Pharmacological effects of the simultaneous and sequential combinations of trifluridine/tipiracil (TAS-102) and 5-fluorouracil in fluoropyrimidine-sensitive colon cancer cells
来源期刊：Investigational New DrugsDOI：10.1007/s10637-019-00804-5
Phase I study of TAS-115, a novel oral multi-kinase inhibitor, in patients with advanced solid tumors
来源期刊：Investigational New DrugsDOI：10.1007/s10637-019-00859-4
The metronomic all-oral DEVEC is an effective schedule in elderly patients with diffuse large b-cell lymphoma
来源期刊：Investigational New DrugsDOI：10.1007/s10637-019-00769-5
Ramucirumab as a second line therapy for advanced HCC: a significant achievement or a wasted opportunity for personalised therapy?
来源期刊：Investigational New DrugsDOI：10.1007/s10637-019-00760-0
Tetra-substituted pyrrole derivatives act as potent activators of p53 in melanoma cells
来源期刊：Investigational New DrugsDOI：10.1007/s10637-019-00813-4
Impact of l-carnitine on imatinib-related muscle cramps in patients with gastrointestinal stromal tumor
来源期刊：Investigational New DrugsDOI：10.1007/s10637-019-00860-x
Reduced expression of annexin A1 promotes gemcitabine and 5-fluorouracil drug resistance of human pancreatic cancer
来源期刊：Investigational New DrugsDOI：10.1007/s10637-019-00785-5
Early depth of tumor shrinkage and treatment outcomes in non-small cell lung cancer treated using Nivolumab
来源期刊：Investigational New DrugsDOI：10.1007/s10637-019-00770-y
Assessment of the cytotoxic effects of aporphine prototypes on head and neck cancer cells
来源期刊：Investigational New DrugsDOI：10.1007/s10637-019-00784-6
Evaluation of the potential effect of dacomitinib, an EGFR tyrosine kinase inhibitor, on ECG parameters in patients with advanced non-small cell lung cancer
来源期刊：Investigational New DrugsDOI：10.1007/s10637-019-00887-0
A new BET inhibitor, 171, inhibits tumor growth through cell proliferation inhibition more than apoptosis induction
来源期刊：Investigational New DrugsDOI：10.1007/s10637-019-00818-z
Novel thiosemicarbazones induce high toxicity in estrogen-receptor-positive breast cancer cells (MCF7) and exacerbate cisplatin effectiveness in triple-negative breast (MDA-MB231) and lung adenocarcinoma (A549) cells
来源期刊：Investigational New DrugsDOI：10.1007/s10637-019-00789-1
Mass balance and metabolite profiling of 14C-guadecitabine in patients with advanced cancer
来源期刊：Investigational New DrugsDOI：10.1007/s10637-019-00854-9
TS-1 add-on therapy in Japanese patients with triple-negative breast cancer after neoadjuvant or adjuvant chemotherapy: a feasibility study
来源期刊：Investigational New DrugsDOI：10.1007/s10637-019-00829-w
A pilot study on intermittent every other days of 5-dose Filgrastim compared with single Pegfilgrastim in breast Cancer patients receiving adjuvant Docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy
来源期刊：Investigational New DrugsDOI：10.1007/s10637-019-00863-8
投稿咨询
加急服务
论文发表
2-4个月录用
7500+文章录用
不成功可退款
